This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma | MicrobiomeTrials
← Back to trials NCT05711615
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma Recruiting PHASE1 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2024-02-06Est. Completion: 2026-11-03
Enrollment target: 30 participantsLocations Los Angeles General Medical Center, Los Angeles, California, United States USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States UCHealth University of Colorado Hospital, Aurora, Colorado, United States University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois, United States University of Chicago Medicine-Orland Park, Orland Park, Illinois, United States Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States Dana-Farber Cancer Institute, Boston, Massachusetts, United States University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States Washington University School of Medicine, St Louis, Missouri, United States Siteman Cancer Center-South County, St Louis, Missouri, United States UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States Other microbiome trials you might be interested in Metastatic Dedifferentiated Liposarcoma Metastatic Undifferentiated Pleomorphic Sarcoma Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 Unresectable Dedifferentiated Liposarcoma Unresectable Undifferentiated Pleomorphic Sarcoma
This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherap…
Phoenix, United States Est. completion Apr 18, 2032
UT MD Anderson Cancer Center, Houston, Texas, United States
University of Virginia Cancer Center, Charlottesville, Virginia, United States Dedifferentiated Liposarcoma Soft Tissue Sarcoma Sarcoma,Soft Tissue Sarcoma Recurrent Dedifferentiated Liposarcoma Unresectable Dedifferentiated Liposarcoma Metastatic Dedifferentiated Liposarcoma
Participants will have a diagnosis of dedifferentiated liposarcoma (DDLS) that has spread beyond its original location (…
Basking Ridge, United States Est. completion May 23, 2027
Solid Tumor Sarcoma Leiomyosarcoma Dedifferentiated Liposarcoma
This early phase oncology trial will be conducted at various study centers to investigate the safety, tolerability, and …
San Francisco, United States Est. completion Dec 29, 2027